Plowing ahead after its latest setback, Axovant nabs two assets to beef up gene therapy pipeline
Fresh from the spectacular failure of its dementia drug, nelotanserin, which has been pushed to the scrap heap along with its much-hyped Alzheimer’s asset, Axovant $AXON is moving on fast at the behest of its deal hungry patron Vivek Ramaswamy.
On Thursday, the company said it had struck a deal to license the global rights to develop and market two gene therapy programs designed to address two progressive and fatal pediatric lysosomal storage disorders: GM1 gangliosidosis and GM2 gangliosidosis – also known as Tay-Sachs and Sandhoff diseases – from the University of Massachusetts Medical School.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.